Download PDF
Der Klinikarzt 2011; 40(9): 419-421
DOI: 10.1055/s-0031-1291958
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Multiple Sklerose – Neue Therapieoptionen

Gerd Meyer zu Hörste
1   Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf
,
Bernd C Kieseier
1   Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
26 September 2011 (online)

Also available at
    Permissions and Reprints

Die Multiple Sklerose (MS) ist eine chronisch entzündlich demyelinisierende Erkrankung des zentralen Nervensystems (ZNS). Mit einer jährlichen Inzidenz von 3,5–5/100 000 Einwohner stellt die MS die häufigste Ursache für dauerhafte Behinderung junger Erwachsener dar. Gemeinsames Charakteristikum aller Verlaufsvarianten ist eine vermutlich autoimmunologisch vermittelte Destruktion von Markscheiden (Myelin) und Axonen des ZNS mit resultierenden Funktionsstörungen. Neben der bekannten Standardtherapie haben sich in letzter Zeit weitere Therapieformen etabliert. In klinischen Studien werden weitere neue Therapien untersucht.

 

  • Literatur

  • 1 Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717
    CrossrefPubMedGoogle Scholar
  • 2 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
    CrossrefPubMedGoogle Scholar
  • 3 Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011; 76: 14-25
    CrossrefPubMedGoogle Scholar
  • 4 Kieseier BC, Wiendl H, Leussink VI, Stuve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 2008; 255 (Suppl. 06) 15-21
    CrossrefPubMedGoogle Scholar
  • 5 Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
    CrossrefPubMedGoogle Scholar
  • 6 Warnke C, Adams O, Gold R et al. Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?. Nervenarzt 2011; 82: 475-480
    CrossrefPubMedGoogle Scholar
  • 7 Rudick RA, O'Connor PW, Polman CH et al. 2010. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68: 304-310
    CrossrefPubMedGoogle Scholar
  • 8 Kappos L, Radue EW, O'Connor P et al. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401
    CrossrefPubMedGoogle Scholar
  • 9 Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
    CrossrefPubMedGoogle Scholar
  • 10 Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426
    CrossrefPubMedGoogle Scholar
  • 11 Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472
    CrossrefPubMedGoogle Scholar
  • 12 O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
    CrossrefPubMedGoogle Scholar
  • 13 Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092
    CrossrefPubMedGoogle Scholar
  • 14 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502
    CrossrefPubMedGoogle Scholar
  • 15 Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738
    CrossrefPubMedGoogle Scholar
  • 16 Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707-714
    CrossrefPubMedGoogle Scholar